HIV-associated wasting prevalence in the era of modern antiretroviral therapy.

ABSTRACT:

Objective

To understand the prevalence of HIV-associated wasting (HIVAW) in the United States.

Design

Medical and pharmacy claims study using IBM MarketScan Commercial, Medicare Supplemental and Medicaid Databases.

Methods

Study period: July 2012-September 2018 (first HIV diagnosis claim = HIV index date). People with HIV (PWH) were excluded if they were aged less than 18 years, had any malignancy claim or had less than 6 months of enrollment data pre or post-HIV index date. HIVAW was defined by proxy using claims for weight loss-related diagnoses, appetite stimulant/nontestosterone anabolic agents or enteral/parenteral nutrition. Prevalence was reported cumulatively, by insurance type and antiretroviral therapy (ART) pharmacy claims (defined as ≥1 pharmacy claim of a

SUBMITTER: Siddiqui J 

PROVIDER: S-EPMC8654247 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature